The U.S. Food and Drug Administration (FDA) recently approved three new medications. Read more below and click on the links provided to access the full FDA press release for each medication online.
- The agency approved BioCryst Pharmaceuticals’ Rapivab (peramivir), the first neuraminidase inhibitor approved for intravenous administration to treat influenza in adults. The treatment, made by Durham, N.C.-based BioCryst Pharmaceuticals, is intended for patients 18 years and older who have acute uncomplicated flu and who have shown symptoms for no more than two days.
- Bristol-Myers Squibb won accelerated FDA approval for Opdivo (nivolumab), a new treatment for patients with unresectable or metastatic melanoma who no longer respond to other drugs.
- The agency also gave the nod to Saxenda (liraglutide [rDNA origin] injection), a treatment option for chronic weight management in addition to reduced calorie intake and physical activity. The drug, approved with a Risk Evaluation and Mitigation Strategy (REMS), is manufactured by Novo Nordisk.